UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Blood, 2014-05, Vol.123 (20), p.3073-3079

2014

Volltextzugriff (PDF)

International Staging System for Multiple Myeloma

Journal of clinical oncology, 2005-05, Vol.23 (15), p.3412-3420

2005

Volltextzugriff (PDF)

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

Journal of clinical oncology, 2008-06, Vol.26 (16), p.2737-2744

2008

Volltextzugriff (PDF)

Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

International journal of hematology, 2011-03, Vol.93 (3), p.351-360

2011

Volltextzugriff (PDF)

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

British journal of haematology, 2015-09, Vol.170 (6), p.804-813

2015

Volltextzugriff (PDF)

Impact of the conditioning regimen in patients with multiple myeloma who undergo autologous transplantation

Journal of clinical oncology, 2011-05, Vol.29 (15), p.e449; author reply e450-e449

2011

Volltextzugriff (PDF)

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

The Journal of molecular diagnostics : JMD, 2017, Vol.19 (1), p.99-106

2017

Volltextzugriff (PDF)

P848: EXPRESSION PROFILE OF BCL‐2 FAMILY PROTEINS IN MULTIPLE MYELOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e8080195-n/a

2023

Volltextzugriff (PDF)

Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

Leukemia & lymphoma, 2015-02, Vol.56 (2), p.415-419

2015

Volltextzugriff (PDF)

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

British journal of haematology, 2013-10, Vol.163 (2), p.223-234

2013

Volltextzugriff (PDF)

Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial

Leukemia & lymphoma, 2009-01, Vol.50 (2), p.216-222

2009

Volltextzugriff (PDF)

Cefepime plus amikacin versus piperacillin–tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

Journal of antimicrobial chemotherapy, 2002-07, Vol.50 (1), p.79-88

2002

Volltextzugriff (PDF)

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

Biology of blood and marrow transplantation, 2013, Vol.19 (1), p.69-74

2013

Volltextzugriff (PDF)

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

Blood, 2008-10, Vol.112 (7), p.2709-2712

2008

Volltextzugriff (PDF)

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group

European journal of haematology, 2008-03, Vol.80 (3), p.227-235

2008

Volltextzugriff (PDF)

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

The Lancet. Haematology, 2022-06, Vol.9 (6), p.e403-e414

2022

Volltextzugriff (PDF)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

Blood cancer journal (New York), 2021-05, Vol.11 (5), p.101-11, Article 101

2021

Volltextzugriff (PDF)

Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study

Biology of blood and marrow transplantation, 2009-04, Vol.15 (4), p.512-516

2009

Volltextzugriff (PDF)

Signet‐ring cell lymphoma. Ultrastructural and immunohistochemical features of three varieties

Cancer, 1983-11, Vol.52 (9), p.1613-1623

1983

Volltextzugriff (PDF)

Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Blood, 2007-11, Vol.110 (11), p.4928-4928

2007

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(29)
Berichte
(1)

Sprache

Englisch
(30)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Aged
(18)
Female
(18)
Male
(18)
Middle Aged
(15)
Hematology
(13)
Adult
(11)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Oncology
(9)
Multiple Myeloma
(8)
Hematologic And Hematopoietic Diseases
(7)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(7)
Multiple Myeloma - Drug Therapy
(7)
Prognosis
(7)
Survival Rate
(7)
Transplantation, Autologous
(7)
Aged, 80 And Over
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

International Staging System for Multiple Myeloma

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

Impact of the conditioning regimen in patients with multiple myeloma who undergo autologous transplantation

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

P848: EXPRESSION PROFILE OF BCL‐2 FAMILY PROTEINS IN MULTIPLE MYELOMA

Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial

Cefepime plus amikacin versus piperacillin–tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study

Signet‐ring cell lymphoma. Ultrastructural and immunohistochemical features of three varieties

Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma : a genome-wide single nucleotide polymorphism analysis. Commentary

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Commentary

Suchergebnisse filtern